VAXCYTE, INC. (PCVX) Current Ratio
- Current ratio · latest quarter: Value 5.72×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 5.72× | Current assets / current liabilities. $1.55B ÷ $271.28M ≈ 5.72× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.55B USD | Assets, Current |
| Current obligations | 271.28M USD | Liabilities, Current |
| Cash and equivalents | 183.19M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 100.92M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.55B | $271.28M | $183.19M | (m) | (m) | (m) | $100.92M | (m) | 5.72× |
| 2026-03-31 | $1.81B | $242.08M | $260.84M | (m) | (m) | (m) | $63.06M | (m) | 7.49× |
| 2025-12-31 | $1.63B | $205.75M | $173.96M | (m) | (m) | (m) | $70.90M | (m) | 7.91× |
| 2025-09-30 | $1.77B | $200.05M | $281.08M | (m) | (m) | (m) | $48.96M | (m) | 8.83× |
| 2025-06-30 | $1.72B | $154.49M | $306.74M | (m) | (m) | (m) | $31.41M | (m) | 11.11× |
| 2025-03-31 | $1.72B | $97.00M | $346.85M | (m) | (m) | (m) | $20.51M | (m) | 17.70× |
| 2024-12-31 | $1.79B | $140.18M | $387.88M | (m) | (m) | (m) | $48.45M | (m) | 12.75× |
| 2024-09-30 | $2.21B | $123.79M | $1.05B | (m) | (m) | (m) | $18.22M | (m) | 17.88× |
| 2024-06-30 | $1.48B | $82.85M | $518.67M | (m) | (m) | (m) | $10.47M | (m) | 17.88× |
| 2024-03-31 | $1.52B | $87.10M | $611.51M | (m) | (m) | (m) | $21.72M | (m) | 17.42× |
| 2023-12-31 | $1.10B | $145.34M | $397.45M | (m) | (m) | (m) | $14.59M | (m) | 7.54× |
| 2023-09-30 | $1.30B | $85.56M | $545.13M | (m) | (m) | (m) | $15.70M | (m) | 15.14× |
| 2023-06-30 | $1.31B | $60.22M | $531.03M | (m) | (m) | (m) | $16.27M | (m) | 21.76× |
| 2023-03-31 | $840.67M | $52.75M | $380.45M | (m) | (m) | (m) | $11.62M | (m) | 15.94× |
| 2022-12-31 | $942.55M | $40.52M | $834.66M | (m) | (m) | (m) | $9.79M | (m) | 23.26× |
| 2022-09-30 | $369.76M | $39.31M | $278.40M | (m) | (m) | (m) | $5.49M | (m) | 9.41× |
| 2022-06-30 | $363.73M | $30.47M | $238.17M | (m) | (m) | (m) | $7.04M | (m) | 11.94× |
| 2022-03-31 | $342.22M | $27.25M | $201.74M | (m) | (m) | (m) | $4.80M | (m) | 12.56× |
| 2021-12-31 | $256.35M | $28.72M | $68.98M | (m) | (m) | (m) | $6.76M | (m) | 8.93× |
| 2021-09-30 | $302.95M | $47.46M | $112.04M | (m) | (m) | (m) | $25.71M | (m) | 6.38× |
| 2021-06-30 | $301.53M | $40.70M | $151.00M | (m) | (m) | (m) | $23.70M | (m) | 7.41× |
| 2021-03-31 | $324.71M | $55.02M | $198.94M | (m) | (m) | (m) | $31.86M | (m) | 5.90× |
| 2020-12-31 | $389.00M | $46.86M | $386.20M | (m) | (m) | (m) | $29.79M | (m) | 8.30× |
| 2020-09-30 | $400.83M | $39.61M | $397.05M | (m) | (m) | (m) | $10.69M | (m) | 10.12× |
| 2020-06-30 | $413.06M | $32.89M | $410.05M | (m) | (m) | (m) | $2.56M | (m) | 12.56× |
| 2019-12-31 | $61.72M | $11.05M | $58.98M | (m) | (m) | (m) | $3.38M | (m) | 5.58× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |